1
Carl R Illig, Shelley K Ballentine, Jinsheng Chen, Sanath K Meegalla, M Jonathan Rudolph, Mark J Wall, Kenneth J Wilson, Renee L Desjarlais, Carl L Manthey, Christopher Flores, Christopher J Molloy: Inhibitors of c-fms kinase. Janssen Pharmaceutical, Mary A Appollina, January 12, 2010: US07645755 (20 worldwide citation)

The invention is directed to compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune disea ...


2
Carl R Illig, Shelley K Ballentine, Jinsheng Chen, Sanath K Meegalla, M Jonathan Rudolph, Mark J Wall, Kenneth J Wilson, Renee L Desjarlais, Carl L Manthey, Christopher Flores, Christopher J Molloy: Inhibitors of c-fms kinase. Janssen Pharmaceutica, Mary A Appollina, February 16, 2010: US07662837 (19 worldwide citation)

The invention is directed to compounds of Formula I: wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune disea ...


3
Shelley K Ballentine, Christian Andrew Baumann, Jinsheng Chen, Carl R Illig, Sanath K Meegalla, M Jonathan Rudolph, Robert W Tuman, Mark J Wall, Kenneth Wilson, Dana L Johnson: Method of inhibiting FLT3 kinase. Janssen Pharmaceutica, Mary A Appollina, September 14, 2010: US07795279 (17 worldwide citation)

A method of reducing or inhibiting kinase activity of FLT3 in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 using a compound of the present invention: or a solvate, hydrate, tautomer or pharma ...


4
Carl R Illig, Nalin L Subasinghe, James B Hoffman, Kenneth J Wilson, M Jonathan Rudolph, Roger F Bone, Scott L Klein, Troy L Randle: Compounds and compositions for treating C1s-mediated diseases and conditions. 3 Dimensional Pharmaceuticals, Sterne Kessler Goldstein & Fox P L L C, February 4, 2003: US06515002 (10 worldwide citation)

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I


5

6

7
Carl R Illig, Nalin L Subasinghe, James B Hoffman, Kenneth J Wilson, M Jonathan Rudolph, Roger F Bone, Scott L Klein, Troy L Randle: Methods of treating C1s-mediated diseases and conditions and compositions thereof. 3 Dimensional Pharmaceuticals, Sterne Kessler Goldstein & Fox P L L C, December 10, 2002: US06492403 (8 worldwide citation)

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I


8
Nalin Subasinghe, Ehab Khalil, Kristi Leonard, Farah Ali, Heather Rae Hufnagel, Jeremy M Travins, Shelley K Ballentine, Kenneth T Wilson, Maxwell D Cummings, Wenxi Pan, Joan Gushue, Sanath Meegalla, Mark Wall, Jinsheng Chen, M Jonathan Rudolph, Hui Huang: Thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions. 3 Dimensional Pharmaceuticals, September 19, 2006: US07109354 (6 worldwide citation)

Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a solvate, hydrate or pharmaceu ...


9

10
Carl R Illig, Shelley K Ballentine, Jinsheng Chen, Sanath K Meegalla, M Jonathan Rudolph, Mark J Wall, Kenneth J Wilson, Renee Louise Desjarlais, Carl M Manthey, Christopher J Molloy: Method of inhibiting C-KIT kinase. Janssen Pharmaceutica, December 27, 2016: US09526731

A method of reducing or inhibiting kinase activity of C-KIT in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to C-KIT using a compound of the present invention: or a solvate, hydrate, tautomer or phar ...